Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty

Effect of preemptive analgesia with parecoxib sodium on multimodal analgesia in primary unilateral total hip arthroplasty: A prospective randomized double-blind controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800014846

Enrollment

Unknown

Registered

2018-02-09

Start date

2014-12-01

Completion date

Unknown

Last updated

2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteonecrosis of the femoral head, femoral neck fracture, developmental dysplasia of hip, osteoarthritis, rheumatoid arthritis or ankylosing spondylitis

Interventions

Experiment group:preoperative intravenous parecoxib sodium and postoperative intravenous parecoxib sodium and patient-controlled analgesia

Control Group:preoperative intravenous pure 0.9% saline and postoperative intravenous parecoxib sodium and patient-controlled analgesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients over the age of 18 with intact cognitive function; 2. Diagnosed as osteonecrosis of the femoral head, femoral neck fracture, developmental dysplasia of hip, osteoarthritis, rheumatoid arthritis and ankylosing spondylitis with unsatisfactory response to conservative treatment, waiting for unilateral total hip arthroplasty; 3. Volunteer to participate in this study and comply with the study protocal; 4. American Society of Anesthesiologists (ASA) = 2; 5. An unified configuration of PCA pump was applied postoperatively.

Exclusion criteria

Exclusion criteria: 1) Allergic to parecoxib sodium, or any composite of the parecoxib sodium product; 2) History of severe allergic reaction, especially dermatological manifestations, including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, or known history of allergic to sulfamide; 3) Active gastrointestinal bleeding or ulceration; 4) Allergic to NSAIDS (including COX-2 inhibitors); 5) Pregnancy or breast-feeding; 6) Severe liver dysfunction (serum albumin < 25 g/L, or Child-Pugh score = 10); 7) Inflammatory bowel disease; 8) Congestive heart failure [New York Heart Association (NYHA) II to IV]; 9) Ischemic cardiac diseases; 10) Disease of peripheral arteries or cerebral vessels; 11) Hip replacement due to acute trauma or revision; 12) Bilateral THA was scheduled.

Design outcomes

Primary

Measure	Time frame
Visual analogue scale;	—

Secondary

Measure	Time frame
Fentanyl consumption;Rescue analgesia consumption;	—

Countries

China

Contacts

Public ContactXisheng Weng

Peking Union Medical College Hospital

xshweng@medmail.com.cn+86 13366200018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026